Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition transactions related to executive compensation plans.
Material Changes
No material changes to financial performance or operational status are reported in this filing. The document details specific increases in notional interests in Ordinary Shares and American Depositary Shares (ADSs) following the re-investment of dividends paid on April 11, 2013.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out based on the vesting percentage of deferred annual bonus holdings after a three-year measurement period.
Key Facts for Investor Verification
- Transaction Date: April 15, 2013.
- Share Prices: Transactions occurred at 1549.50 pence per Ordinary Share and $47.75 per ADS.
- Participants: Includes Sir Andrew Witty, Mr S Dingemans, Mr S M Bicknell, Mrs D P Connelly, Mr W C Louv, Mr D S Redfern, Dr M M Slaoui, Ms C Thomas, Mr D E Troy, Dr P J T Vallance, and Ms E Walmsley.
- Transaction Type: Acquisitions of Ordinary Shares and ADSs under both personal contribution and company matching elements of the Deferred Annual Bonus Plan.
- Regulatory Basis: Notification made in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).